Kornimate/medical-research-clean huggingface dataset:
impact of early intensive stimulation on bimanual function in infants at high risk of unilateral cp (bb-bim)

Conditions: Cerebral Palsy

Summary: the aim of this study is to measure the impact of early bimanual stimulation in babies with clinical signs of underuse of one hand. the observation focuses on the developmental curve of hands use. the intervention is provided by the family environment and takes place in the child's familiar surroundings.

congenital hemiplegia, often referred to as unilateral cerebral palsy (ucp), is characterized by a unilateral or asymmetrical brain injury that occurs around birth and impacts the development of manual skills and motor abilities of one side of the body. affected children frequently develop hemiplegia with major limitations in the use of their impaired hand, resulting in poor bimanual coordination, thus impacting the performance of daily activities at home, school and in the community. several intensive therapy approaches currently exist, including the bimanual approach (bim) which aims to improve the use of the affected hand as an assisting hand in daily functional activities. these approaches have long been established as effective, however, with these children reaching 90% of their potential gross motor skills around the age of 5, or even earlier in some cases, there is a growing interest in earlier approaches, well before school age. it has also long been established that during the first year of life, there is a critical time frame for hand motor development. the investigators have thus set up an intensive bimanual stimulation program for infants showing early signs of ucp, delivered by the family environment, in the child's familiar surroundings, under the guidance of a therapist, over a period of 2 months.

Eligibility criteria:
inclusion criteria: * baby between 3 and 12 months of age at the time of inclusion * clinical signs of underuse of one of the two upper limbs, (reported by the parents and authenticated by the hai) * unilateral brain injury * brain imaging performed at birth or upon initial parental concerns * possibility of a home visit by the occupational therapist * at least one parent volunteering to actively participate in the intensive stimulation * parental consent to enter the study * consent for image rights exclusion criteria: * prematurity * lack of interest suggesting underlying associated disorders * active epilepsy

Keywords: unilateral cerebral palsy unilateral brain lesion infantile cerebral palsy
armor (analyzing renal mechanisms of creatinine excretion in patients on tesaglitazar)

Conditions: Diabetes Mellitus, Type 2

Summary: this is a prospective 24-week, randomized, parallel-group, multi-center, active-controlled (pioglitazone 45 mg) open-label study designed to assess the effects of tesaglitazar 2 mg per day on components of renal excretion of creatinine in type 2 diabetics. the study comprises a 2-week enrollment period, followed by a 24-week double blind treatment period and an 8-week follow-up period


Eligibility criteria:
inclusion criteria: * provision of a written informed consent * men or women who are \>=45 years of age * female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control * diagnosed with type 2 diabetes * treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents exclusion criteria: * type 1 diabetes * new york heart association heart failure class iii or iv * treatment with chronic insulin * history of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like actos or avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor (statin) * history of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells) * creatinine levels above twice the normal range * creatine kinase above 3 times the upper limit of normal * received any investigational product in other clinical studies within 12 weeks * any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study

Keywords: type 2 diabetes
evaluation of two different types of zirconia crowns used in carious primary anterior teeth

Conditions: Dental Caries in Children

Summary: evaluation of two different types of zirconia crowns ( kinder krown , nusmile crown) used in carious primary anterior teeth

assess the clinical and radiographic evaluation of kinder krowns and nusmile crowns in restoring carious primary canines and compare between the two crowns used

Eligibility criteria:
inclusion criteria: * children age ranging from 7 to 10 years * deep carious primary upper canines * the tooth need pulpal treatment * the tooth need a crown restoration * the tooth not submerged * the tooth is not mobile exclusion criteria: * children with bruxism or deep bite * children with especial need * presence of pathological root resorption in preoperative x-ray * presence of tooth wear (abrasion/attrition) on the opposing teeth

Keywords: zirconia crowns in pediatric dentistry dental caries aesthetic primary teeth restoration
icmnc-hf. intracoronary bone marrow mononuclear cells in heart failure (hf) patients

Conditions: Heart Failure

Summary: this is a prospective, randomised double blind, controlled, parallel-group phase i and ii study. its aim is to assess that a single intracoronary infusion of autologous bone marrow-mononuclear cells is safe and effective in hear failure patients with reduced left ventricular ejection fraction(\<=30%) when compared to a control group of patients undergoing best medical care.


Eligibility criteria:
inclusion criteria: 1. men and women of any ethnic origin 18 ≤ aged≤ 65 years 2. ef≤40 (by echocardiography) and regional wall motion abnormality 3. not responding to standard therapies 4. the new york heart association (nyha) class ≥ iii 5. myocardial infarction due to coronary artery atherosclerotic disease 6. an area of regional dysfunction, i.e., hypokinetic, akinetic, or dyskinetic (echocardiography or mri) 7. normal liver and renal function 8. no or controlled diabetes 9. able to give voluntary written consent and understand the study information provided to him exclusion criteria: 1. participation in another clinical trial within 30 days prior randomisation 2. previously received stem/progenitor cell therapy 3. pregnant women 4. mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study or to follow the protocol 5. cardiogenic shock requiring mechanical support 6. congenital / valvular heart disease 7. implantable cardioverter defibrillator (icd) transplant 8. platelet count \<100.000/µl, or hemoglobin \<8.5 g/dl 9. impaired renal function, i.e. creatinine \>2.5 mg/dl 10. fever or diarrhea within 4 weeks prior screening 11. history of bleeding disorder within 3 months prior screening 12. uncontrolled hypertension (systolic \>180 mmhg and diastolic \>120 mmhg) or sustained ventricular arrhythmia 13. life expectancy of less than two years from any non-cardiac cause or uncontrolled neoplastic disease
study to actively warm trauma patients

Conditions: Massive Blood Loss; Hypothermia

Summary: this study evaluates the feasibility of using thermal blankets to actively warm massively bleeding trauma patients at sunnybrook health sciences centre. it is hypothesized that either full thermal blankets or half thermal blankets will be a feasible intervention to implement for the care of massively bleeding trauma patients.

hypothermia (core body temperature of \<36˚c), is a strong risk factor for mortality and poor outcomes in trauma patients due to its negative hemostatic, cardiovascular, respiratory, and renal effects. current evidence has reported that massively bleeding hypothermic trauma patients have higher odds of mortality in the first 24 hours of hospital admission, increased length of stay, and increased need for transfusion. standard hospital blankets are used to passively warm patients through resuscitation and treatment until arrival to the icu. interventions such as active heating through thermal blankets should be considered to prevent and treat hypothermia upon arrival of patients than standard warmed hospital blankets to prevent deleterious outcomes in this population.

Eligibility criteria:
inclusion criteria: * any trauma patient requiring activation of the massive hemorrhage protocol (life- threatening bleeding situation requiring mobilization of blood bank, laboratory and clinical resources, and anticipated need for at least 4 units of red blood cells immediately and component therapy) during the hours when research staff are available. normothermic (core body temperature between 36˚c or greater) will also be included, as core body temperature drops once resuscitation is initiated. * hypothermic patients (temperature ≤ 35˚c) to whom mhp is not activated, when dr. luis da luz/trauma fellow is on call as trauma team leader will also be included. exclusion criteria: * patients known to be pregnant * patients who die in the trauma bay * patients excluded at the discretion of the ttl based on use of the blanket not appearing feasible given the sustained injuries, multiple procedures being conducted in the trauma, or patients who seem to have unsurvivable injuries. * patients admitted during study off-hours.

Keywords: warming blankets trauma bleeding
oscar endo one stop assessment of risk for endometrial hyperplasia and cancer

Conditions: Endometrial Cancer; Atypical Hyperplasia

Summary: it is to be achieved that in postmenopausal women through the combination of hysteroscopy and intraoperative rapid section a positive predictive value (ppv) regarding the objective illness like endometrial cancer or adenomatous hyperplasia of 100% so as a negative predictive value (npv) of 99%.

if a patient fulfills the inclusion criteria, the surgeon decides intraoperatively due to the aspect in the hysteroscopy if it is a clearly benign result or if it looks suspicious or malign. in case of a hysteroscopical benign result the patient will be informed about the result after the operation. in case of a hysteroscopal suspicious or malignant aspect, the curettement will be sent for a rapid section. if the hysteroscopic result confirms the hysteroscopic suspicion the patient will be informed after the operation and the further treatment can be planned right away.

Eligibility criteria:
inclusion criteria: * postmenopausal status (more than 1 year of last menopausal bleeding) * postmenopausal vaginal bleeding * asymptomatic postmenopausal endometrial hyperplasia * understanding of the german language * signature and consent of the patient exclusion criteria: * not able to understand and participate in the study * premenopausal status * no informed consent

Keywords: postmenopausal bleeding postmenopausal hyperplasia endometrial cancer atypical hyperplasia curettage intraoperative rapid section
cardiac perfusion and metabolism with [11c] acetate pet/ct is associated with hematopoietic system activation in acute decompensated heart failure: an imaging sub-study

Conditions: Acute Decompensated Heart Failure

Summary: the purpose of this sub-study is to use positron emission tomography and computed tomography imaging (pet/ct) with an investigational drug called \[11c\] acetate to see if inflammation in patients with acute decompensated heart failure (adhf) can cause changes in blood flow and oxygen use in the heart. this study may help physicians better understand how to treat patients diagnosed with adhf in the future.


Eligibility criteria:
inclusion criteria: * at least 18 years of age. * enrollment in the uab cmc-adhf study under the separate uab approved research protocol (irb-300000114, pi rajapreyar) * negative urine or serum β-hcg test within 48 hours of \[11c\] acetate administration in women of child bearing potential. women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing. exclusion criteria: * inability to provide informed consent * pregnancy * inability to lie still for the imaging study * weight exceeding the weight limit of the pet imaging table (500 pounds).
application of 18f-fdopa pet and magnetic resonance spectroscopy (mrs) with hcv and pd

Conditions: Hepatitis C; Hepatitis B; Parkinson Disease

Summary: the objective of this study is to investigate the evidence of dopaminergic toxicity causing by hcv infection using 18f-fdopa pet and mrs as imaging biomarkers.

parkinson's disease (pd) is the most common neurodegenerative disorder after alzheimer's disease. it is characterized by degeneration of the dopaminergic neurons in substantia nigra and striatum, even before the clinical symptoms develop. although the pathogenesis is still unclear, some viruses have been shown to be associated with acute or chronic parkinsonism. recent studies have found that hepatitis c virus (hcv) can replicate in the central nervous system, suggesting a possible link between pd and hcv. at the population and epidemiology level, the hcv infection and pd are strongly associated. at the molecular level, both hcv and pd have in common the overexpression of inflammatory biomarkers. neuronal toxicity induced by hcv was also demonstrated. the positive association between hcv infection and pd has clinical implications for high endemic hcv areas, including taiwan. 18f-fdopa, an analog to l-dopa, has been used as a positron-emitting compound for pet examination of patients affected by pd. it has been shown that putamen 18f-fdopa uptakes are reduced by at least 35% at onset of symptoms, making the 18f-fdopa pet as an imaging biomarker for detecting subclinical and preclinical parkinsonism. earlier imaging study using magnetic resonance spectroscopy (mrs) to investigate cerebral effect of hcv also showed that chronic hcv infection had elevated choline/creatine ratios, a biomarker indicating inflammatory and infective conditions, in the basal ganglia and white matter. the objective of this study is to investigate the evidence of dopaminergic toxicity causing by hcv infection using 18f-fdopa pet and mrs as imaging biomarkers.

Eligibility criteria:
inclusion criteria: * test group 1. age：above 20 years old with hbv or hcv subjects. 2. patient agrees to participate in the study and receive updrs, mmse, bdi ii, mri and pet imaging. * control group 1. age：above 20 years old without carriers of hepatitis b and c (ex. fatty liver), and no known neurological (ex. stroke, parkinson's disease and degenerative neuropathy, etc.) and mental illness. 2. patient agrees to participate in the study and receive updrs, mmse, bdi ii, mri and pet imaging. exclusion criteria: 1. patients could not receive pet and mri studies, including panic mood to mri study, allergy to contrast medium, hemodynamic instability. 2. patients with pregnancy or recently having a plan for pregnancy. 3. patient or family who does not agree to participate in the study

Keywords: hepatitis c hepatitis b parkinson's disease 18f-fdopa pet, mrs mrs
high dimensional analysis of immune cells in pediatric patients

Conditions: Drug Allergy; Neuromuscular Blockade

Summary: the purpose of this study is to characterize immune cells using single-cell transcriptomic analysis in pediatric patients aged 2 to 18 years undergoing general anesthesia who are expected to receive rocuronium, a non-depolarizing neuromuscular blocking agent, in the event of an allergic reaction.


Eligibility criteria:
inclusion criteria: * pediatric patients between the ages of 2 and 18 undergoing general anesthesia and surgery using the neuromuscular blocker, rocuronium. exclusion criteria: * patients who have received immunomodulators, immunosuppressants, etc. * patients with autoimmune diseases (rheumatoid arthritis, lupus, behcet's disease, etc.) * patients who regularly take, or have taken within 4 weeks, medications that may affect the immune system (oral steroids, anti-inflammatories, etc.) * other cases where the principal investigator determines that it is difficult to conduct the study.
prospective multicenter research on donor and recipient management strategies to improve lung transplant outcomes

Conditions: Lung Transplant; Complications; Lung Transplant; Infection or Inflammation; Lung Transplant Rejection; Lung Transplant Failure

Summary: this project aims to collect detailed clinical data, blood samples, and patient-reported outcomes from 2,600 lung transplant candidates, donors, and recipients at lung transplant centers. the goal is to create a robust resource for various research objectives, including studying the impact of variations in donor and medical practices on clinical outcomes. the project also seeks to identify serum biomarkers associated with or predictive of specific post-transplant complications and conditions.

this is an observational, prospective, multicenter cohort study of 2,600 lung transplant donors and adult (18 years and older) lung transplant candidates and recipients that will collect longitudinal clinical data, and serial biological (blood) specimens and pros to support a broad range of clinical and translational future research. data and biospecimens will be rigorously collected and monitored to ensure high quality future studies that will address unmet needs and optimal management at each stage of the transplant journey from listing, to donor selection, to postoperative management. subjects are recruited to the study either prior to undergoing lung transplant at the time of listing or within 30 days of having undergone a lung transplant at one of the enrolling centers. the study design will generally follow the soc practices at each center to minimize additional research related visits. participants will follow the soc transplant protocols at each site. every attempt will be made by the site to collect study data and research specimens from participants at the time of soc visits. participation in this study will include scheduled data extraction or data transfers at specified time intervals, serial prospective blood collection (including plasma, serum), recipient dna sample collection (with donor dna sample collection optional), and pro measures.

Eligibility criteria:
inclusion criteria: 1. able to understand and provide informed consent 2. ≥ 18 years of age at the time of written informed consent 3. anticipated listing or listed for a single or bilateral cadaveric donor lung transplant or having received a lung transplant within 30 days * participants undergoing repeat lung transplantation or multi-organ transplantation are eligible if they meet the inclusion/exclusion criteria. exclusion criteria: 1. unwillingness of a participant or legally authorized representative (lar) to give written informed consent or comply with study protocol 2. pregnancy or plans to become pregnant 3. past or current medical problems or findings from physical examination or laboratory testing, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
probiotic supplement as treatment for students with adhd

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)

Summary: subjects will answer the following questionnaire and tests: * symptom severity and improvement will be measured using adha rating scale iv (adhd rs) * demographic questionnaire - composed by the researchers * family eating habits questionnaire (feahq-33) * food frequency questionnaire (ffq) * test moxo the subjects will take the study product for six months. after six months the subject will fill once again all the questionnaires.

computerized performance test moxo - the test has been developed in israel by neurotech company. the test's goal is to assess and define a participant's performance according to the four indices of attention deficit hyperactivity disorder: attention, hyperactivity, impulsivity, and timing with adjustment for age. subjects will answer the following questionnaire and tests: * symptom severity and improvement will be measured using adha rating scale iv (adhd rs) * demographic questionnaire - composed by the researchers * family eating habits questionnaire (feahq-33) * food frequency questionnaire (ffq) * test moxo the subjects will take the study product for six months. after six months the subject will fill once again all the questionnaires.

Eligibility criteria:
inclusion criteria: * students registered in the college's support center for students with learning disabilities and who have been diagnosed by a computerized didactic assessment -matal - as well as an attention diagnosis by a psychiatrist or a neurologist, * students who are not treated by medication or alternative treatment, * students who are not due to complete their education at tel hai college during the study period, * students who have signed on an informed consent form, * no dairy intolerance (student can consume milk without any adverse effects), * no soy allergy, * not currently taking any antibiotics or probiotics, * not pregnant or planning to become pregnant during the study period, * not been diagnosed with any of the following: * cancer * hiv/aids * crohn's disease * ulcerative colitis * immune compromised illness * other serious illness exclusion criteria: * students treated by any type of treatment for attention deficit hyperactivity disorder, * students who have not been assessed by matal and a psychiatrist, * students who take antibiotics.
utility of a molecular personalized coronary gene expression test (corus cad or asges) on cardiology practice pattern

Conditions: Angina Pectoris; Coronary Artery Disease; Chest Pain; Cardiovascular Diseases; Coronary Heart Disease; CAD; CVD; CHD

Summary: to investigate whether the use of corus cad (age/sex/gene expression score - asges) blood assay changes the diagnostic testing pattern in patients referred to a cardiologist for the evaluation of chest pain or anginal equivalent symptoms.

a prospective cohort of 88 subjects receiving the corus cad (age/sex/gene expression score - asges) assay were compared to a retrospective cohort of 83 subjects that did not receive the assay.

Eligibility criteria:
inclusion criteria: 1. stable chest pain, typical or atypical angina or anginal equivalent 2. the patient has signed the appropriate institutional review board approved informed consent form. exclusion criteria: 1. history of myocardial infarction 2. current myocardial infarct (mi) or acute coronary syndrome 3. current new york heart association (nyha) class iii or iv congestive heart failure symptoms 4. any previous coronary revascularization 5. any individuals with: 1. diabetes 2. suspected unstable angina 3. systemic infections 4. systemic inflammatory conditions 6. any individuals currently taking: 1. steroids 2. immunosuppressive agents 3. chemotherapeutic agents 7. recipient of any organ transplant

Keywords: corus cad age/sex/gene expression score molecular genetics atherosclerosis asges gene expression ges cad cvd chd clinical utility precision medicine coronary artery disease angina pectoris chest pain cardiovascular disease coronary heart disease impact impact-card